RT Journal Article
SR Electronic
T1 Quantitative EEG Spectral Features Differentiate Genetic Epilepsies and Predict Neurologic Outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.09.24315105
DO 10.1101/2024.10.09.24315105
A1 Galer, Peter D.
A1 McKee, Jillian L.
A1 Ruggiero, Sarah M.
A1 Kaufman, Michael C.
A1 McSalley, Ian
A1 Ganesan, Shiva
A1 Ojemann, William K.S.
A1 Gonzalez, Alexander K.
A1 Cao, Quy
A1 Litt, Brian
A1 Helbig, Ingo
A1 Conrad, Erin C.
YR 2024
UL http://medrxiv.org/content/early/2024/10/10/2024.10.09.24315105.abstract
AB EEG plays an integral part in the diagnosis and management of children with genetic epilepsies. Nevertheless, how quantitative EEG features differ between genetic epilepsies and neurological outcomes remains largely unknown. Here, we aimed to identify quantitative EEG biomarkers in children with epilepsy and a genetic diagnosis in STXBP1, SCN1A, or SYNGAP1, and to assess how quantitative EEG features associate with neurological outcomes in genetic epilepsies more broadly.We analyzed individuals with pathogenic variants in STXBP1 (95 EEGs, n=20), SCN1A (154 EEGs, n=68), and SYNGAP1 (46 EEGs, n=21) and a control cohort of individuals without epilepsy or known cerebral disease (847 EEGs, n=806). After removing artifacts and epochs with excess noise or altered state from EEGs, we extracted spectral features. We validated our preprocessing pipeline by comparing automatically-detected posterior dominant rhythm (PDR) to annotations from clinical EEG reports. Next, as a coarse measure of pathological slowing, we compared the alpha-delta bandpower ratio between controls and the different genetic epilepsies. We then trained random forest models to predict a diagnosis of STXBP1, SCN1A, and SYNGAP1. Finally, to understand how EEG features vary with neurological outcomes, we trained random forest models to predict seizure frequency and motor function.There was strong agreement between the automatically-calculated PDR and clinical EEG reports (R2=0.75). Individuals with STXBP1-related epilepsy have a significantly lower alpha-delta ratio than controls (P<0.001) across all age groups. Additionally, individuals with a missense variant in STXBP1 have a significantly lower alpha-delta ratio than those with a protein-truncating variant in toddlers (P<0.001), children (P=0.02), and adults (P<0.001). Models accurately predicted a diagnosis of STXBP1 (AUC=0.91), SYNGAP1 (AUC=0.82), and SCN1A (AUC=0.86) against controls and from each other in a three-class model (accuracy=0.74). From these models, we isolated highly correlated biomarkers for these respective genetic disorders, including alpha-theta ratio in frontal, occipital, and parietal electrodes with STXBP1, SYNGAP1, and SCN1A, respectively. Models were unable to predict seizure frequency (AUC=0.53). Random forest models predicted motor scores significantly better than age-based null models (P<0.001), suggesting spectral features contain information pertinent to gross motor function.In summary, we demonstrate that STXBP1-, SYNGAP1-, and SCN1A-related epilepsies have distinct quantitative EEG signatures. Furthermore, EEG spectral features are predictive of some functional outcome measures in patients with genetic epilepsies. Large-scale retrospective quantitative analysis of clinical EEG has the potential to discover novel biomarkers and to quantify and track individuals’ disease progression across development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementEC received support from the NINDS (K23 NS121401-01A1) and the Burroughs Wellcome Fund. IH is supported by the Center for Epilepsy and Neurodevelopmental Disorders (ENDD), NINDS (R01 NS127830-01A1, R01 NS131512-01, and K02 NS112600), St. Jude's (1U24NS120854-02 and 1U24NS120854-03), the Hartwell Foundation (Individual Biomedical Research Award), and the Dravet Foundation. BL is supported by NINDS (DP1NS122038) and The Jonathan Rothberg Family Fund. JLM is supported by SynGAP Research Fund (SRF) through a Research Training Fellowship for Clinicians.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of Children's Hospital of Philadelphia gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll deidentified data produced are available online at https://github.com/galerp/scalp_EEG_DEE/. https://github.com/galerp/scalp_EEG_DEE/